Pharmaceuticals
CStone Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK
* This approval marks the second international marketing authorization for sugemalimab outside ofChina, following its recent approval by the European Commission. * The approval is based on results from the Phase 3 GEMSTONE-302 clinical trial, which demonstrated that sugemalimab in combination...
2024-10-31 13:00
1880
Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA, locally advanced or metastatic EGFR-mutant NSCLC
CHENGDU, China, Oct. 31, 2024 /PRNewswire/ -- The new drug application (NDA) (the "Application") based on the positive results from the pivotal phase III OptiTROP-Lung04 study of sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) developed by Sichuan Kelun-Biotech Biopharmaceutical Co., L...
2024-10-31 12:34
1561
Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA, locally advanced or metastatic EGFR-mutant NSCLC
CHENGDU, China, Oct. 31, 2024 /PRNewswire/ -- The new drug application (NDA) (the "Application") based on the positive results from the pivotal phase III OptiTROP-Lung04 study of sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) developed by Sichuan Kelun-Biotech Biopharmaceutical Co., L...
2024-10-31 12:02
1461
Breakthrough Australian Cancer trial: retraining immune cells offers new hope for patients
ADELAIDE, Australia and BOSTON, Oct. 31, 2024 /PRNewswire/ -- In a remarkable development for cancer research, Australian patients with advanced-stage cancer have benefited from SUPLEXA, a personalised treatment that trains the patient's own immune cells to fight cancer. "Cancer often gains th...
2024-10-31 12:00
1668
Abionic's CAPSULE PSP Receives FDA Approval for Early Detection of Sepsis; Fapon Introduces Exclusive PSP Solution in China via Licensing Collaboration
DONGGUAN, China, Oct. 30, 2024 /PRNewswire/ -- Fapon, a global leading life sciences company, is thrilled to announce its PSP CLIA reagent solution which demonstrates promising outcomes in extensive clinical validation studies targeting Chinese population. Leveraging its strategic partnership ...
2024-10-31 10:26
1299
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined with Ligufalimab (CD47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (HNSCC), Compared to Pembrolizumab
HONG KONG, Oct. 30, 2024 /PRNewswire/ -- Akeso Biopharma (9926.HK) is pleased to announce the enrollment of the first patient in its randomized, controlled, multicenter Phase III clinical study (AK117-302) for head and neck squamous cell carcinoma. This trial evaluates the innovative PD-1/VEGF bi...
2024-10-31 08:46
1949
Latest Updates of Viva Biotech's Portfolio Companies
HONG KONG, Oct. 30, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the suc...
2024-10-30 22:24
1949
I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024
- Poster to be presented in a late-breaking abstract session at the Society for Immunotherapy of Cancer (SITC) onSaturday, November 9, 2024 ROCKVILLE, Md., Oct. 30, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the develop...
2024-10-30 19:00
1005
World Stroke Congress | TASTE-2 significantly reduces stroke disability
NANJING, China, Oct. 30, 2024 /PRNewswire/ -- Oct 24th 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that a new clinical study with major clinical findings regarding Sanbexin (edaravone and dexborneol concentrated solution for injection) has been published at the 16th World Stroke...
2024-10-30 15:36
1242
WuXi AppTec Named Global CRDMO Company of the Year by Frost & Sullivan for the Eighth Consecutive Year
SHANGHAI, Oct. 29, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been awarded the 2024 Global CRDMO Company of the Year Award by Frost & Sullivan, a gr...
2024-10-30 08:00
1181
Celltrion presents post hoc analysis of LIBERTY studies of ZYMFENTRA® (infliximab-dyyb) at the American College of Gastroenterology 2024 Annual Scientific Meeting
* Pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) previously demonstrated superior efficacy of subcutaneous (SC) infliximab over placebo for maintenance therapy in patients with Crohn's disease (CD) and ulcerative colitis (UC)[1], [2] * ZYMFENTRA® is the first and only FDA-approved subcut...
2024-10-30 03:25
1231
LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
GAITHERSBURG, Md., Oct. 29, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for i...
2024-10-29 20:30
2152
GemVax Announces Topline Results from Phase 2a Progressive Supranuclear Palsy Clinical Trial at Neuro2024
- Topline supports moving to Phase 3 trial and shows potential to develop GV1001 as the world's first PSP treatment SEOUL, South Korea, Oct. 29, 2024 /PRNewswire/ -- GemVax & KAEL Co., Ltd. ("GemVax"; KOSDAQ ticker: 082270) announced that topline results of a Phase 2a clinical trial (the ...
2024-10-29 19:27
2197
Discovery of cancer risk associations for six novel genes
REYKJAVIK, Iceland, Oct. 29, 2024 /PRNewswire/ --Scientists at deCODE genetics/Amgen, and their collaborators have discovered six novel genes with rare germline variants that associate with cancer risk. The findings are published today in Nature Genetics under the title "Gene-based burden tests o...
2024-10-29 18:00
1381
RemeGen Announces the Acceptance of the Marketing Application of Telitaccept for the Treatment of Myasthenia Gravis in China
YANTAI, China, Oct. 29, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently announced that the marketing application of Taicercept ® for the treatment of generalized myasthenia gravis (gMG) has been officially...
2024-10-29 12:00
1358
The 21st World Congress of Chinese Medicine - Seminar on the Integration of Industry and Education in Cardiovascular and Cerebrovascular Diseases Kicks off in Paris
PARIS, Oct. 29, 2024 /PRNewswire/ -- On October 25, 2024, the 21st World Congress of Chinese Medicine (WCCM) commenced at the United Nations Educational, Scientific and Cultural Organization (UNESCO) Headquarters in Paris, France. A key highlight of the WCCM was the Seminar on the Integratio...
2024-10-29 11:01
1411
GC Biopharma and Novelty Nobility Enter into Joint Research and Development Agreement for Geographic Atrophy Therapies
YONGIN, South Korea, Oct. 28, 2024 /PRNewswire/ -- GC Biopharma announced that it has signed an agreement with Novelty Nobility, a biotech company specializing in the development of antibody-based therapeutics, for the joint research and development of a novel treatment for geographic atrophy (GA...
2024-10-29 09:13
1668
Innovent Announces Results of a Phase 2 Study of Picankibart (Anti-IL-23p19 Antibody) in Plaque Psoriasis, Showing Efficacy in Patients with Prior Inadequate Response to IL-17 Biologics
SAN FRANCISCO and SUZHOU, China, Oct. 29, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...
2024-10-29 07:57
1550
Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK's AREXVY
-- Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of non-adjuvanted bivalent RSV vaccine candidate (SCB-1019) -- -- RSV neutralizing antibodies for Clover's non-adjuvanted SCB-1019 matched GSK's AS01E-adjuvanted AREXVY in older adults, while d...
2024-10-29 06:32
1405
KIND Presents Positive Results of AND017 to Treat Anemia Associated with Chronic Kidney Disease in Two Phase II and Two Phase I
Clinical Trials at American Society of Nephrology (ASN) – Kidney Week 2024 SAN FRANCISCO, Oct. 28, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to...
2024-10-29 05:42
999
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
6217
